<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02174445</url>
  </required_header>
  <id_info>
    <org_study_id>CAMN107ADE18T</org_study_id>
    <secondary_id>2013-000077-68</secondary_id>
    <secondary_id>DRKS00006285</secondary_id>
    <nct_id>NCT02174445</nct_id>
  </id_info>
  <brief_title>An Open-label, Randomised Multicenter Phase 3b Study to Determine the Confirmed Rate of Molecular Response ≥ 4 Log (MR4) at Two Years</brief_title>
  <acronym>DECLINE</acronym>
  <official_title>Imatinib Continuation Versus Nilotinib 300 mg Twice Daily in Patients With Chronic Myeloid Leukemia (CML) in Chronic Phase and Major Molecular Re-sponse (MMR) Without Molecular Response ≥ 4.5 Log (MR4.5) Receiving Imatinib at a Dose of 400 to 800 mg Daily. An Open-label, Randomised Multicenter Phase 3b Study to Determine the Confirmed Rate of Molecular Response ≥ 4 Log (MR4) at Two Years</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Prof. Dr. Nikolas von Bubnoff</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital Freiburg</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, multicenter, randomised phase 3b clinical trial of Imatinib 400 to 800
      mg daily versus Nilotinib 300 mg two times daily in chronic phase CML patients with confirmed
      MMR without MR4.5
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-label, multicenter, randomised phase 3b clinical trial of Imatinib 400 to 800
      mg daily versus Nilotinib 300 mg two times daily in chronic phase CML patients with confirmed
      MMR without MR4.5 (after having received Imatinib 400 to 800 mg daily for at least 18 months)
      to determine the proportion of patients with confirmed MR4 after two years. Patients in
      treatment arm A (Imatinib) who do not achieve confirmed MR4 2 years after randomisation will
      be offered cross-over from Imatinib 400 to 800 mg daily to Nilotinib 300 mg twice daily. One
      hundred thirty-two (132) patients will be included and randomised 1:1 to each treatment arm.

      The study will be stratified by duration of Imatinib treatment before screen-ing (≤36 months
      / &gt;36 months) as well as by the level of response at inclusion (MMR / MR4).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Anticipated">December 2024</completion_date>
  <primary_completion_date type="Anticipated">October 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients with confirmed MR4 after two years of study treatment</measure>
    <time_frame>2 years</time_frame>
    <description>Proportion of patients with confirmed MR4 at two years of study treatment in both treatment arms. Confirmed MR4 at two years is defined as either BCR-ABL ≤ 0.01% IS at 21 and 24 months or BCR-ABL ≤ 0.01% IS at 24 months and confirmation within six weeks</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">132</enrollment>
  <condition>Chronic Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>Imatinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Imatinib 400-800mg, daily, maximum 6 years</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nilotinib</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Nilotinib, 300mg, twice daily, maximum 6 years</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Imatinib</intervention_name>
    <description>Imatinib, 400 to 800 mg p.o., daily</description>
    <arm_group_label>Imatinib</arm_group_label>
    <other_name>Glivec</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nilotinib</intervention_name>
    <description>300mg p.o., twice-daily</description>
    <arm_group_label>Nilotinib</arm_group_label>
    <other_name>Tasigna</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Signed written informed consent

          2. Male or female patients aged &gt;=18 years (without upper limit of age)

          3. ECOG performance status of 0 to 2

          4. CML in chronic phase, with chronic phase defined as blasts &lt; 15% in blood and/or bone
             marrow and peripheral blood basophils &lt; 20% and platelets ≥ 100 G/L

          5. Pretreatment with Imatinib with a treatment duration of at least 18 months at a dosage
             of 400 to 800 mg daily

          6. Major molecular response (MMR) without molecular response ≥ 4.5 log (MR4.5), i.e.
             BCR-ABL&gt;0.0032% and ≤0.1% IS confirmed by central la-boratory at screening will be
             required for randomisation

          7. Patients must have a serum Creatinine of ≤ 1.5 x ULN, SGOT ≤ 1.5 x ULN, total
             bilirubin ≤ 1.5 x ULN (except known M. Gilbert), and Lipase ≤ 1.5 x ULN

          8. Women of child-bearing potential defined as sexually mature women who have not
             undergone a hysterectomy or who have not been naturally postmenopausal for at least 12
             consecutive months, must have a negative serum pregnancy test during screening period.
             Male and fe-male patients of reproductive potential must agree to employ highly
             ef-fective methods of birth control throughout the study and for up to 3 months
             following discontinuation of study drug. Appropriate methods are e.g. a highly
             effective method of first choice, i.e. a method with a low failure rate (less than 1%
             per year) like sexual abstinence, com-bined oral contraceptives, implants, injectable,
             some Intra Uterine Devices (IUDs), vasectomized partner, in combination with a method
             of second choice like condom, diaphragm, or cup pessary with spermicidal
             foam/gel/film/cream/suppository.

        Exclusion Criteria:

          1. Any previous treatment for CML other than Hydroxyurea, Imatinib or Interferon alpha

          2. Evidence of features of accelerated or blast phase at any time

          3. Previous loss of hematologic or cytogenetic response

          4. Concomitant medications known to be strong inducers or inhibitors of P450 Isoenzyme
             CYP3A4

          5. Finding of a secondary BCR-ABL resistance mutation at any time

          6. History of intolerance to Imatinib that required treatment interruption longer than 4
             weeks (cumulative) or dose reductions to less than 400 mg daily for longer than 4
             weeks (cumulative) during the last 12 months before informed consent

          7. Patients who had prior allogeneic, syngeneic, or autologous bone mar-row transplant or
             stem cell transplant

          8. Patients unwilling to or unable to comply with the planned therapeutic intervention or
             to comply with the study treatment visits including blood sample collection within the
             protocol

          9. History of pancreatitis, chronic inflammatory diseases or autoimmune diseases

         10. Patients who underwent solid organ transplantation

         11. Impaired cardiac function, including any of the following:

               -  History of or presence of complete left bundle branch block, right bundle branch
                  block plus left anterior hemi block, bifascicular block in screening ECG

               -  Use of a cardiac pacemaker

               -  ST depression of &gt; 1mm in 2 or more leads and/or T wave inver-sions in 2 or more
                  contiguous leads in screening ECG

               -  Congenital Long QT Syndrome

               -  QTc&gt; 450 msec in the screening ECG

               -  QT prolonging concomitant medication

               -  History of or presence of significant ventricular or atrial tachy-arrhythmia in
                  screening ECG

               -  History of or presence of clinically significant resting bradycardia (&lt; 50 beats
                  per minute)

               -  Myocardial infarction within 12 months prior to informed consent

               -  Unstable angina diagnosed or treated during the past 12 months before informed
                  consent

               -  Other clinically significant heart disease (e.g., congestive heart fail-ure,
                  uncontrolled hypertension, history of labile hypertension)

         12. Known HIV and/or hepatitis B or C infection (testing is not mandatory)

         13. Other malignancies within the past 3 years before informed consent except for
             adequately treated carcinoma of the cervix and basal or squamous cell carcinoma of the
             skin

         14. Women who are pregnant or breast feeding

         15. Male/female patients of reproductive potential unwilling to practice a highly
             effective method of birth control

         16. History of noncompliance to medical regimens

         17. Treatment with another investigational product during this study or during the last 30
             days prior to informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nikolas von Bubnoff, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Freiburg</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nikolas von Bubnoff, Professor</last_name>
    <email>nikolas.bubnoff@uniklinik-freiburg.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Universitätsklinikum Aachen</name>
      <address>
        <city>Aachen</city>
        <zip>52074</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Tim Brümmendorf, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Praxis Dr. Bruder / Dr. Heinrich / Prof. Bangerter</name>
      <address>
        <city>Augsburg</city>
        <zip>86150</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Bernhard Heinrich, Dr. med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Bonn</name>
      <address>
        <city>Bonn</city>
        <zip>53105</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Viktor Janzen, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gemeinschaftspraxis</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Thomas Illmer, PD Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Praxis Dr. Hauch</name>
      <address>
        <city>Erfurt</city>
        <zip>99084</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ulrich Hauch, Dr. med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Internistische Schwerpunktpraxis Erlangen oncosearch</name>
      <address>
        <city>Erlangen</city>
        <zip>91052</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Michael Eckart, Dr. med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Praxis für Hämatologie/Onkologie Dres. Rudolph, Sengpiel, von Verschuer</name>
      <address>
        <city>Essen</city>
        <zip>45136</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ulla von Verschuer, Dr. med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Medical Center</name>
      <address>
        <city>Freiburg</city>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nikolas von Bubnoff, Professor</last_name>
      <email>nikolas.bubnoff@uniklinik-freiburg.de</email>
    </contact>
    <investigator>
      <last_name>Nikolas von Bubnoff, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Hamburg-Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Philippe Schafhausen, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Jena</name>
      <address>
        <city>Jena</city>
        <zip>07747</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Andreas Hochhaus, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinik Köln</name>
      <address>
        <city>Köln</city>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Christof Scheid, PD Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gemeinschaftspraxis Hämatologie/Onkologie</name>
      <address>
        <city>Magdeburg</city>
        <zip>39104</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Kathleen Jentsch-Ulrich, PD Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinikum Mannheim GmbH Universitätsklinikum</name>
      <address>
        <city>Mannheim</city>
        <zip>68167</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Martin C. Mueller, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Überörtliche Gemeinschaftspraxis Hämato-Onkologie Pasing/Fürstenfeldbruck</name>
      <address>
        <city>Munich</city>
        <zip>81241</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Burkhard Schmidt, Dr. med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinikum rechts der Isar, Technische Universität München</name>
      <address>
        <city>München</city>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Philipp Jost, PD Dr. med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Onkologische Praxis Oldenburg</name>
      <address>
        <city>Oldenburg</city>
        <zip>26121</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Burkhard Otremba, Dr. med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medizinische Statistik Saarbrücken, GbR</name>
      <address>
        <city>Saarbrucken</city>
        <zip>66113</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Georg Jacobs, Dr. med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Ulm</name>
      <address>
        <city>Ulm</city>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Frank Stegelmann, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 24, 2014</study_first_submitted>
  <study_first_submitted_qc>June 24, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 25, 2014</study_first_posted>
  <last_update_submitted>November 22, 2016</last_update_submitted>
  <last_update_submitted_qc>November 22, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 23, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital Freiburg</investigator_affiliation>
    <investigator_full_name>Prof. Dr. Nikolas von Bubnoff</investigator_full_name>
    <investigator_title>Mr.</investigator_title>
  </responsible_party>
  <keyword>Patients with CML in chronic phase</keyword>
  <keyword>Imatinib</keyword>
  <keyword>Nilotinib</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Imatinib Mesylate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

